NX-2127

NX-2127 is an orally and potent BTK inhibitor, inducing degradation of the mutated BTK^C481S in cells. NX-2127 inhibits proliferation of BTK^C481S mutant TMD8 cells. NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with of 25 nM and 54 nM, respectively. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells.


Cat. No.: EX-A7600	Purity: >98%

	Chemical structure of NX-2127

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	500	In-stock
500mg	900	In-stock
1g	1400	In-stock
2g	2350	In-stock
5g	3850	In-stock
10g	6550	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


CAS No.	2416131-46-7
Purity	>98%
Formula	C39H45N9O5
Mol Weight	719.83
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 3 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Robbins D W, et al. Nx-2127, a degrader of BTK and IMiD neosubstrates, for the treatment of B-cell malignancies. Blood, 2020, 136: 34. [2]. Mato A, et al. A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies. 2022.
Data Sheet	Data sheet of NX-2127
CoA	CoA of NX-2127
SDS	SDS of NX-2127


		Search